• Consensus Rating: Buy
  • Consensus Price Target: $64.50
  • Forecasted Upside: 52.16 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$42.39
▼ -1.58 (-3.59%)

This chart shows the closing price for PCVX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vaxcyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PCVX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCVX

Analyst Price Target is $64.50
▲ +52.16% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vaxcyte in the last 3 months. The average price target is $64.50, with a high forecast of $70.00 and a low forecast of $52.00. The average price target represents a 52.16% upside from the last price of $42.39.

This chart shows the closing price for PCVX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Vaxcyte.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2022BTIG ResearchInitiated CoverageBuy$69.00Low
11/8/2022Cantor FitzgeraldBoost Target$55.00 ➝ $70.00Low
10/24/2022Bank of AmericaBoost Target$67.00Low
2/24/2022Needham & Company LLCReiterated RatingBuy$52.00High
8/14/2020Needham & Company LLCReiterated RatingBuy$52.00Low
7/7/2020Bank of AmericaInitiated CoverageBuy$37.00High
7/7/2020Jefferies Financial GroupInitiated CoverageBuyHigh
7/7/2020Needham & Company LLCInitiated CoverageBuy$40.00High
7/7/2020Cantor FitzgeraldInitiated CoverageOverweight$55.00High
(Data available from 12/10/2017 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/14/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/11/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2022
  • 15 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/10/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Vaxcyte logo
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $42.39
Low: $42.30
High: $44.93

50 Day Range

MA: $37.49
Low: $20.58
High: $46.06

52 Week Range

Now: $42.39
Low: $16.78
High: $47.67

Volume

442,247 shs

Average Volume

585,468 shs

Market Capitalization

$3.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Vaxcyte?

The following sell-side analysts have issued stock ratings on Vaxcyte in the last twelve months: Bank of America Co., BTIG Research, Cantor Fitzgerald, and Needham & Company LLC.
View the latest analyst ratings for PCVX.

What is the current price target for Vaxcyte?

4 Wall Street analysts have set twelve-month price targets for Vaxcyte in the last year. Their average twelve-month price target is $64.50, suggesting a possible upside of 52.2%. Cantor Fitzgerald has the highest price target set, predicting PCVX will reach $70.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $52.00 for Vaxcyte in the next year.
View the latest price targets for PCVX.

What is the current consensus analyst rating for Vaxcyte?

Vaxcyte currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCVX will outperform the market and that investors should add to their positions of Vaxcyte.
View the latest ratings for PCVX.

What other companies compete with Vaxcyte?

How do I contact Vaxcyte's investor relations team?

Vaxcyte's physical mailing address is 353 HATCH DRIVE, FOSTER CITY CA, 94404. The company's listed phone number is 650-837-0111 and its investor relations email address is [email protected] The official website for Vaxcyte is www.vaxcyte.com. Learn More about contacing Vaxcyte investor relations.